Glioblastoma: Why immunotherapy may offer hope for brain cancer patients

Glioblastoma is the most common and deadliest form of brain cancer. Patients face a bleak prognosis—the average survival after diagnosis is between 12 and 15 months. And just 6.9% of patients survive beyond five years, making it one of the most poorly survived cancers.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup